Clinical Trials · NCT01468181
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 394
- Start date
- Nov 2011
- Locations
- 14 sites, Japan
- Primary endpoint
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)